DrugPatentWatch Database Preview
Details for Patent: 7,732,490
» See Plans and Pricing
Which drugs does patent 7,732,490 protect, and when does it expire?
Patent 7,732,490 protects ZOLINZA and is included in one NDA.
This patent has ninety patent family members in twenty-eight countries.
Summary for Patent: 7,732,490
| Title: | Methods of treating cancer |
| Abstract: | The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo. |
| Inventor(s): | Richon; Victoria M. (Rye, NY), Chiao; Judy H. (Berkeley Heights, NJ), Kelly; William Kevin (Scotch Plains, NJ), Miller; Thomas A. (Brookline, MA) |
| Assignee: | Merck HDAC Research, LLC (Boston, MA) Sloan-Kettering Institute for Cancer Research (New York, NY) |
| Application Number: | 11/853,700 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 7,732,490
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck | ZOLINZA | vorinostat | CAPSULE;ORAL | 021991-001 | Oct 6, 2006 | RX | Yes | Yes | Start Trial | Start Trial | TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WTIH CUTANEOUS T-CELL LYMPHOMA (CTCL) | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,732,490
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 462426 | Start Trial | |||
| Australia | 2003213684 | Start Trial | |||
| Australia | 2004266169 | Start Trial | |||
| Australia | 2004283717 | Start Trial | |||
| Australia | 2008246251 | Start Trial | |||
| Australia | 2009201668 | Start Trial | |||
| Brazil | 0308250 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
